MA26671A1 - COMPOSITION PHARMACEUTIQUE POUVANT eTRE ADMINISTRÉE PAR VOIE ORALE CONTENANT UN INHIBITEUR DE LIPASE GASTRO-INTESTINALE, UN (OU PLUSIEURS) ADDITIF(S) DU GROUPE CONSTITUE PAR LES ÉPAISSISSANTS, ET ÉMULSIFIANTS DE QUALITÉ ALIMENTAIRE MÉDIOCREMENT DIGESTIBLES, MÉDIOCREMENT FERMENTABLES, HYDROPHILES ET OU HYDROCOLLOiDAUX ET DES EXCIPIENTS AUXILIAIRES - Google Patents

COMPOSITION PHARMACEUTIQUE POUVANT eTRE ADMINISTRÉE PAR VOIE ORALE CONTENANT UN INHIBITEUR DE LIPASE GASTRO-INTESTINALE, UN (OU PLUSIEURS) ADDITIF(S) DU GROUPE CONSTITUE PAR LES ÉPAISSISSANTS, ET ÉMULSIFIANTS DE QUALITÉ ALIMENTAIRE MÉDIOCREMENT DIGESTIBLES, MÉDIOCREMENT FERMENTABLES, HYDROPHILES ET OU HYDROCOLLOiDAUX ET DES EXCIPIENTS AUXILIAIRES

Info

Publication number
MA26671A1
MA26671A1 MA25725A MA25725A MA26671A1 MA 26671 A1 MA26671 A1 MA 26671A1 MA 25725 A MA25725 A MA 25725A MA 25725 A MA25725 A MA 25725A MA 26671 A1 MA26671 A1 MA 26671A1
Authority
MA
Morocco
Prior art keywords
hyrodiocredely
hyrodiocredriately
digiously
digious
médiocre
Prior art date
Application number
MA25725A
Other languages
English (en)
Inventor
Manuela Hug
Hans-Peter Maerki
Marcel Meier
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26671A1 publication Critical patent/MA26671A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • General Preparation And Processing Of Foods (AREA)
MA25725A 1998-08-14 1999-08-11 COMPOSITION PHARMACEUTIQUE POUVANT eTRE ADMINISTRÉE PAR VOIE ORALE CONTENANT UN INHIBITEUR DE LIPASE GASTRO-INTESTINALE, UN (OU PLUSIEURS) ADDITIF(S) DU GROUPE CONSTITUE PAR LES ÉPAISSISSANTS, ET ÉMULSIFIANTS DE QUALITÉ ALIMENTAIRE MÉDIOCREMENT DIGESTIBLES, MÉDIOCREMENT FERMENTABLES, HYDROPHILES ET OU HYDROCOLLOiDAUX ET DES EXCIPIENTS AUXILIAIRES MA26671A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98115311 1998-08-14
EP99109516 1999-05-12

Publications (1)

Publication Number Publication Date
MA26671A1 true MA26671A1 (fr) 2004-12-20

Family

ID=26149537

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25725A MA26671A1 (fr) 1998-08-14 1999-08-11 COMPOSITION PHARMACEUTIQUE POUVANT eTRE ADMINISTRÉE PAR VOIE ORALE CONTENANT UN INHIBITEUR DE LIPASE GASTRO-INTESTINALE, UN (OU PLUSIEURS) ADDITIF(S) DU GROUPE CONSTITUE PAR LES ÉPAISSISSANTS, ET ÉMULSIFIANTS DE QUALITÉ ALIMENTAIRE MÉDIOCREMENT DIGESTIBLES, MÉDIOCREMENT FERMENTABLES, HYDROPHILES ET OU HYDROCOLLOiDAUX ET DES EXCIPIENTS AUXILIAIRES

Country Status (19)

Country Link
US (1) US6358522B1 (fr)
EP (1) EP1105122B1 (fr)
JP (1) JP3774118B2 (fr)
KR (1) KR20010079635A (fr)
CN (1) CN1170534C (fr)
AR (1) AR035001A1 (fr)
AT (1) ATE293970T1 (fr)
AU (1) AU761351B2 (fr)
BR (1) BR9912980B1 (fr)
CA (1) CA2340056C (fr)
CO (1) CO5130009A1 (fr)
DE (1) DE69924999T2 (fr)
DK (1) DK1105122T3 (fr)
ES (1) ES2242413T3 (fr)
MA (1) MA26671A1 (fr)
PE (1) PE20000953A1 (fr)
PT (1) PT1105122E (fr)
TR (1) TR200100471T2 (fr)
WO (1) WO2000009122A1 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7048917B1 (en) 1998-01-09 2006-05-23 Genzyme Corporation Fat-binding polymers
US6264937B1 (en) * 1998-01-09 2001-07-24 Geltex Pharmaceuticals, Inc. Fat-binding polymers
US6299868B1 (en) 1999-07-14 2001-10-09 Geltex Pharmaceuticals, Inc. Fat-binding polymers
AU745697B2 (en) 1998-09-08 2002-03-28 Smithkline Beecham Corporation Lipstatin derivative-soluble fiber tablets
AR025609A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
AR025587A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
EP1132389A1 (fr) 2000-03-06 2001-09-12 Vernalis Research Limited Nouveaux dérivés de l'azaindole pour le traitement de l'obésité
ES2269441T3 (es) * 2000-06-27 2007-04-01 F. Hoffmann-La Roche Ag Metodo para la preparacion de una composicion.
ATE293477T1 (de) 2000-07-28 2005-05-15 Hoffmann La Roche Neue verwendung von lipase-inhibitoren
KR100572785B1 (ko) 2000-07-28 2006-04-19 에프. 호프만-라 로슈 아게 신규한 약학 조성물
CA2417607C (fr) 2000-08-09 2008-01-29 Christine Feinle Utilisation d'inhibiteurs de lipase
WO2002044152A1 (fr) 2000-10-16 2002-06-06 F. Hoffmann-La Roche Ag Derives d'indoline et leur utilisation en tant que ligands de recepteur 5-ht2
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
BR0116605A (pt) 2000-12-27 2003-09-30 Hoffmann La Roche Composto, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e processo para o tratamento e profilaxia de distúrbios do sistema nervoso central, distúrbios cardiovasculares, distúrbios gastrintestinais e apnéia do sono
GB0106177D0 (en) 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
AU2002338896B2 (en) 2001-05-21 2006-04-27 F.Hoffman-La Roche Ag Quinoline derivatives as ligands for the neuropeptide Y receptor
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US6730319B2 (en) * 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
US7041280B2 (en) * 2001-06-29 2006-05-09 Genzyme Corporation Aryl boronate functionalized polymers for treating obesity
US7049345B2 (en) * 2001-06-29 2006-05-23 Genzyme Corporation Fat-binding polymers
US6787558B2 (en) 2001-09-28 2004-09-07 Hoffmann-La Roche Inc. Quinoline derivatives
GB0202015D0 (en) 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
PL372295A1 (en) 2002-02-04 2005-07-11 F.Hoffmann-La Roche Ag Quinoline derivatives as npy antagonists
BR0308108A (pt) 2002-02-28 2004-12-07 Hoffmann La Roche Compostos; processo para a preparação de composto; composição farmacêutica que compreende o mesmo, utilização dos compostos e método de tratamento e profilaxia de enfermidades e de obesidade
PL216022B1 (pl) 2002-04-26 2014-02-28 Hoffmann La Roche Kompozycja farmaceutyczna, sposób jej wytwarzania i jej zastosowanie, zestaw do leczenia otylosci, inhibitor lipazy w postaci orlistatu i glukomannan lub konjac, zastosowanie inhibitora lipazy w postaci orlistatu oraz zastosowanie glukomannanu lub konjacu
CA2489251A1 (fr) 2002-07-05 2004-01-15 F. Hoffmann-La Roche Ag Derives de quinazoline
AU2003253364B2 (en) 2002-08-07 2007-06-07 F. Hoffmann-La Roche Ag Thiazole derivatives
WO2004024726A1 (fr) 2002-09-12 2004-03-25 F. Hoffmann-La Roche Ag Composes d'acide 1h-indol-5-propionique a substitution n en tant qu'agonistes de ppar utiles dans le traitement du diabete
DE60323130D1 (de) 2002-11-25 2008-10-02 Hoffmann La Roche Indolderivaten
US8372430B2 (en) 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
GB0314967D0 (en) 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
CN100393718C (zh) 2003-08-12 2008-06-11 霍夫曼-拉罗奇有限公司 作为npy拮抗剂的噻唑衍生物
CA2533463A1 (fr) 2003-08-12 2005-02-17 F. Hoffmann-La Roche Ag Antagonistes 2-amino-5-benzoylthiazole du npy
CA2609634C (fr) 2005-05-03 2011-02-01 F. Hoffmann-La Roche Ag Azapyrazinoindolines tetracycliques constituant des ligands 5-ht2
JP5044398B2 (ja) 2005-06-09 2012-10-10 武田薬品工業株式会社 固形製剤
DE602006006712D1 (de) 2005-08-18 2009-06-18 Hoffmann La Roche Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
ATE507222T1 (de) 2005-11-30 2011-05-15 Hoffmann La Roche 1,1-dioxo-thiomorpholinyl-indolyl-methanon- derivate zur verwendung als h3-modulatoren
CA2630270A1 (fr) 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag Derives de indole-2-carboxamide substitues en 5
DE602006020482D1 (de) 2005-11-30 2011-04-14 Hoffmann La Roche 1,5-substituierte indol-2-yl amidderivative
ES2333672T3 (es) 2005-12-09 2010-02-25 F. Hoffmann-La Roche Ag Derivados de amida triciclica para tratamiento de obesidad.
CN101326187A (zh) 2005-12-15 2008-12-17 霍夫曼-拉罗奇有限公司 吡咯并[2,3-c]吡啶衍生物
BRPI0619985A2 (pt) 2005-12-16 2011-10-25 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas, métodos para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, de obesidade e de diabetes do tipo ii em um ser humano ou animal e usos dos compostos
US7432255B2 (en) 2006-05-16 2008-10-07 Hoffmann-La Roche Inc. 1H-indol-5-yl-piperazin-1-yl-methanone derivatives
EP2032554A1 (fr) 2006-05-30 2009-03-11 F. Hoffmann-Roche AG Dérivés de pipéridinylpyrimidine
US7514433B2 (en) 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives
US20080146559A1 (en) 2006-12-08 2008-06-19 Li Chen 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives
CA2686257C (fr) * 2007-05-16 2013-07-02 Buckman Laboratories International, Inc. Procedes pour controler des contaminants organiques presents dans des fibres
WO2009013195A1 (fr) 2007-07-25 2009-01-29 F. Hoffmann-La Roche Ag Dérivés d'amide d'acide benzofurane- et benzo[b]thiophène-2-carboxylique et leur utilisation comme modulateurs du récepteur h3 de l'histamine
WO2009044380A2 (fr) 2007-10-05 2009-04-09 Ranbaxy Laboratories Limited Formulations contenant des particules d'orlistat à dimension de particule contrôlée
US20100317642A1 (en) * 2007-10-15 2010-12-16 Inventis Dds Pvt Limited Pharmaceutical composition of orlistat
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
US8309107B2 (en) 2008-10-06 2012-11-13 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
GB201122213D0 (en) * 2011-12-23 2012-02-01 Norgine Bv Compositions
CN104546768B (zh) * 2014-12-30 2017-06-16 重庆植恩药业有限公司 含有脂肪酶抑制剂的咀嚼片组合物及其制备方法
BR112018075415A2 (pt) * 2016-06-17 2019-03-12 The Procter & Gamble Company composição mastigável macia compreendendo plantago
CN112220831A (zh) * 2020-08-07 2021-01-15 天津盛实百草中药科技有限公司 圆苞车前子壳粉在缓解奥利司他副作用中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4005195A (en) * 1976-02-12 1977-01-25 The Procter & Gamble Company Compositions for treating hypercholesterolemia
CA1247547A (fr) 1983-06-22 1988-12-28 Paul Hadvary Derives de leucine
US5294451A (en) * 1991-03-29 1994-03-15 Curtice-Burns, Inc. Fat substitute compositions having reduced laxative effects
CA2098167C (fr) * 1992-06-24 2006-12-19 Dorothea Isler Aliments pour humains et animaux contenant un inhibiteur de la lipase
CA2128044C (fr) * 1993-08-05 2007-02-20 Klaus-Dieter Bremer Compositions pharmaceutiques comportant un glucosidase et/ou un inhibiteur d'amylase, et un inhibiteur des lipases
JPH09252746A (ja) * 1996-03-22 1997-09-30 Nippon Kankyo Yakuhin Kk 栄養補助食品
JP4202439B2 (ja) * 1996-10-01 2008-12-24 江崎グリコ株式会社 フラボノイド可溶化法、その糖転移法及び高濃度フラボノイド溶液
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions

Also Published As

Publication number Publication date
CA2340056C (fr) 2007-01-09
DK1105122T3 (da) 2005-08-08
DE69924999T2 (de) 2006-05-04
PE20000953A1 (es) 2000-09-26
AR035001A1 (es) 2004-04-14
BR9912980A (pt) 2001-05-08
KR20010079635A (ko) 2001-08-22
AU5418599A (en) 2000-03-06
AU761351B2 (en) 2003-06-05
ES2242413T3 (es) 2005-11-01
CA2340056A1 (fr) 2000-02-24
JP2002522491A (ja) 2002-07-23
BR9912980B1 (pt) 2013-10-22
EP1105122A1 (fr) 2001-06-13
CN1312713A (zh) 2001-09-12
ATE293970T1 (de) 2005-05-15
PT1105122E (pt) 2005-08-31
CO5130009A1 (es) 2002-02-27
EP1105122B1 (fr) 2005-04-27
TR200100471T2 (tr) 2001-07-23
DE69924999D1 (de) 2005-06-02
WO2000009122A1 (fr) 2000-02-24
CN1170534C (zh) 2004-10-13
US6358522B1 (en) 2002-03-19
JP3774118B2 (ja) 2006-05-10

Similar Documents

Publication Publication Date Title
CA2340056A1 (fr) Compositions pharmaceutiques comportant des inhibiteurs de lipase
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
CA2340052A1 (fr) Compositions pharmaceutiques contenant des inhibiteurs de lipases et du chitosane
EP0693281A3 (fr) Formulations pharmaceutiques contenant de la fluoxétine
MA25284A1 (fr) Composition antioxydante, y compris l'acide de l'acetylene, l-carnitine qui ameliore l'utilisation metabolique du glucose.
EP1762557A3 (fr) Mediateurs lipidiques actives par l'aspirine
BR9908438A (pt) Tabletes de desintegração rápida
DZ3165A1 (fr) Composition alimentaire ou pharmaceutique utiliseepour prevenir ou traiter l'hyperoxalurie.
BG103425A (en) Pharmaceutical composition
DE50008336D1 (de) Mehrschichttablette zur verabreichung einer fixen kombination von tramadol und diclofenac
NO2013019I1 (no) Kombinasjon omfattende aliskiren, som den frie basen eller som et farmasøytisk akseptabelt salt derav, og hydroklortiazid eller et farmasøytisk akseptabelt salt derav.
PT951474E (pt) Novos derivados da ciclosporina sua preparacao e composicoes farmaceuticas que os contem
WO2005007137A3 (fr) Comprimés contenant de l'ambroxol
BR0011447A (pt) Composição compreendendo esfingomielinase alcalina para aplicação como uma preparação dietética, suplemento alimentar ou produto farmacêutico
PT1131297E (pt) Certas caprolactamas substituidas composicoes farmaceuticas contendo-as e sua utilizacao no tratamento de tumores
KR920019365A (ko) 디리트로마이신을 함유하는 약학 제형
GB9619660D0 (en) Prevention of gastrointestinal damage
JPS51128438A (en) An antibacterial drug against fish diseases
DE69902999D1 (de) Glucocorticoide zur behandlung von glomerulonephitis
KR970061248A (ko) 알츠하이머병 치료용 1, 1, 2-트리페닐부트-1-엔 유도체
DZ3103A1 (fr) Nouvelles pyrazolo Ä4,3-EÜdiazépines substituées, compositions pharmaceutiques les contenant, utili sation à titre de médicament et procédés pour leurs préparation.
DZ3050A1 (fr) Formes polymorphes d'un citrate d'azobicydoÄ2,2,2Ü-octane-3-amine cristallin et leurs compositions pharmaceutiques.
CA2378724A1 (fr) Composition pour prevenir et traiter les affections et les maladies du rein
WO2001022917A3 (fr) Compositions effervescentes comportant du nimesulide
DE60008392D1 (de) Nicht-hygroskopische salze aktiver inhaltsstoffe, die therapeutische und/oder ernährungsphysiologische eigenschaften haben und oral verabreichbare zusammensetzungen, die diese enthalten